Techno Drugs (DHA:TECHNODRUG) Debt-to-EBITDA : (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT41.40
! 5 Warning Signs
View Full Analysis

What is Techno Drugs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Techno Drugs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was BDT389 Mil. Techno Drugs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was BDT2,429 Mil. Techno Drugs's annualized EBITDA for the quarter that ended in Mar. 2026 was BDT555 Mil. Techno Drugs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was 5.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Techno Drugs's Debt-to-EBITDA or its related term are showing as below:

DHA:TECHNODRUG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.43   Med: 2.56   Max: 4.08
Current: 4.08

During the past 3 years, the highest Debt-to-EBITDA Ratio of Techno Drugs was 4.08. The lowest was 2.43. And the median was 2.56.

DHA:TECHNODRUG's Debt-to-EBITDA is ranked worse than
76.66% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs DHA:TECHNODRUG: 4.08

Techno Drugs  (DHA:TECHNODRUG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Techno Drugs Debt-to-EBITDA Related Terms

Techno Drugs Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Techno Drugs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs Debt-to-EBITDA Chart

Techno Drugs Annual Data
Trend Jun23 Jun24 Jun25
Debt-to-EBITDA
- - -

Techno Drugs Quarterly Data
Sep23 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - - - -

DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Techno Drugs Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Techno Drugs's Debt-to-EBITDA falls into.


DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Techno Drugs's Debt-to-EBITDA for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1029.920309 + 1593.475534) / 1081.969284
=2.42

Techno Drugs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(388.78451 + 2429.083786) / 554.672472
=5.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT41.40
Price